|
Market Report
|
 Psoriasis - Anti-TNF's lead another indication
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.
|
|
Read more...
|
|
|
Market Report
|
What companies need to know about trends in physicians and consumers' use of the Internet
An understanding of the present and future market trends surrounding eHealth is vital in order for the pharmaceutical industry to develop effective multi-channel marketing strategies. It is advisable for stakeholders to invest in targeted initiatives that meet the specific information needs and support the decision making processes of the large numbers of physician and consumer groups online.
|
|
Read more...
|
|
|
Market Report
|
Key trends and strategic issues shaping the industry
Datamonitor has identified the key trends and events that impacted the pharmaceutical market on a macro-environmental and corporate strategy level in 2006. These range from the continuation of long term trends such as the focus on cost containment to more recent impacts such as the effects of Medicare Part D and the increasing power of the Democratic part in the US.
|
|
Read more...
|
|
|
Market Report
|
Esophageal Cancer: Treatment paradigms need revolution not evolution
Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients still present with locally advanced unresectable or distant metastatic disease, where treatment is complicated and chances of a cure are reduced.
|
|
Read more...
|
|
|
Market Report
|
Small Cell Lung Cancer and Malignant Mesothelioma
SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
|
|
Read more...
|
|
|
Market Report
|
Search Engine Marketing, insights and trends for pharmaceutical industry
At the recent e-Marketing Summit in Zürich, organised by Eyeforpharma we have had pleasue to participate at workshop "Search Engine Marketing, insights and trends in Pharma".
|
|
Read more...
|
|
|
Market Report
|
Atopic Dermatitis - A high level of unmet need creates market opportunities
Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader interviews, Datamonitor has identified a high level of unmet need in atopic dermatitis treatment and believe that a number of market opportunities exist.
|
|
Read more...
|
|
|
Market Report
|
ePrescribing - Infrastructure and Impact on the Healthcare Markets in the US
Technology has been used to either inform or expedite the prescribing process in most modern healthcare systems for over two decades. Recently, market forces - including greater regulatory intervention, increased investment from stakeholders and decreased resistance from end-users - have begun to converge to set the stage for widespread adoption of truly integrated ePrescribing solutions.
|
|
Read more...
|
|
|
Market Report
|
Depression - Novel drugs to grow third-line market
Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK's gepirone ER is likely to be the first pipeline drug to enter the market and exploit this opportunity, with forecast sales of $615m in 2016.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 55 - 63 of 238 |
Farmavita.Net Journal 
